AbbVie, Voyager Launch Up-to-$1.1B+ Gene-Therapy Collaboration to Treat Alzheimer’s, Neurodegenerative Diseases – Genetic Engineering & Biotechnology News
Endpoints News |
AbbVie, Voyager Launch Up-to-$1.1B+ Gene–Therapy Collaboration to Treat Alzheimer's, Neurodegenerative Diseases
Genetic Engineering & Biotechnology News AbbVie will partner with Voyager Therapeutics to develop and commercialize gene therapies for Alzheimer's disease and other neurodegenerative diseases, through a collaboration that could generate more than $1.1 billion-plus for Voyager, the companies … With $69M Deal, AbbVie Turns to Voyager for an Alzheimer's Gene Therapy AbbVie steers past the wreckage, reserves $224M to kick off once-and-done gene therapy with Voyager to fight … Voyager Therapeutics (VYGR), AbbVie (ABBV) Enter Pact to Develop Potential New Treatments for Alzheimer's … |
